

Aytu Products Savings Offer

Karbinal[®] ER (carbinoxamine maleate) extended-release oral suspension | 4mg/5mL*

*Each 5mL contains 4 mg carbinoxamine maleate (equivalent to 2.86 mg of carbinoxamine) complexed with sodium polystyrene sulfonate.

Karbinal[®] ER (carbinoxamine maleate) Extended-release Oral Suspension is an H1 receptor antagonist indicated for adult and children 2 years of age and older for the symptomatic treatment of seasonal and perennial allergic rhinitis.

Present to your pharmacist to apply the savings offer

100% of eligible patients with commercial non-governmental insurance may pay as low as†



Per prescription if “covered” on insurance plan and where deductible has been met

— or —



Per prescription if “not covered” on insurance plan or if the deductible has not been met. No prior authorization required

†Terms and conditions apply.

Pharmacist Instructions:

1. Visit www.aytucoupon.com
2. Click “I’m a pharmacy”
3. Input necessary information and press submit
4. Utilize the offer to assist patient

The ACE Customer Excellence Team

If you experience any pharmacy-related issues, call our dedicated staff at 1-888-AYTURxC (298-8792). Support available Monday through Friday, 9:00 am to 7:30 pm ET (except holidays).

Retail Copay Offer Terms and Conditions: This program provides non-government copay assistance with out-of-pocket costs for eligible patients. By using this offer, patient and pharmacist understand and agree to comply with these terms and conditions. Offer may only be used by eligible residents of the U.S. at participating pharmacies and may not be redeemed at government-subsidized clinics. Offer user must be at least 18 years of age to use for themselves or on behalf of a minor. Patient age or insurance restrictions may apply.

Offer limited to one per person and is not transferrable. No substitutions are permitted. Offer eligible only with valid prescription, has no cash value, and cannot be combined with any free trial, discount, prescription savings card or other offer. This offer is not insurance. Valid only for patients with commercial insurance and NOT valid for prescriptions eligible to be reimbursed in whole or in part by Medicaid, Medicare (including Medicare Advantage and Part D plans), or any other federally or state funded healthcare benefit program, or by commercial plans or other health or pharmacy benefit programs that reimburse for entire cost of the prescription drug or prohibit offer’s use. Medicare Part D enrollees who are in the prescription drug coverage gap are not eligible for offer. Void where prohibited by law, taxed or restricted. It is illegal to sell, purchase, trade, or counterfeit, or offer to sell, purchase, trade or counterfeit the offer.

Patient, pharmacist and prescriber agree not to seek reimbursement for all or any part of the benefit received by patient through the offer. Certain information pertaining to use of the offer will be shared with Aytu BioPharma, the sponsor of the offer, and its affiliates. The information disclosed will include the patient copay ID, pharmacy demographics, prescriber information, and details relating to the claim, such as copay amount, insurance details, and therapy received. For more information, please see the Aytu BioPharma privacy policy.

Aytu BioPharma reserves the right to rescind, revoke or amend the offer at any time without notice.

Please see Important Safety Information on the next page for Karbinal ER, and the [Full Prescribing Information](#).

Karbinal[®] ER
(carbinoxamine maleate) extended-release
oral suspension | 4mg/5mL

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about Karbinal ER?

- Karbinal ER is contraindicated in children younger than 2 years of age, and nursing mothers.
- Karbinal ER may produce marked drowsiness and impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
- Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of Karbinal ER. Avoid concurrent use of Karbinal ER with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. Patients should avoid the use of alcoholic beverages, sedatives, and tranquilizers while taking Karbinal ER because additional reduction in mental alertness may occur.
- Avoid use of Karbinal ER with alcohol and other CNS depressants (hypnotics sedatives, tranquilizers, etc.) due to additive effects. Patients should not use MAOIs while taking Karbinal ER. MAOIs may prolong and intensify the anticholinergic (drying) effects.
- Breastfeeding is not recommended during treatment with Karbinal ER.

What are the possible side effects of Karbinal ER?

Use of Karbinal ER may result in decreased mental alertness with impaired mental or physical abilities.

The most frequent side effects include:

- Sedation
- Sleepiness
- Dizziness
- Disturbed coordination
- Epigastric distress
- Thickening of bronchial secretions

Ask your doctor or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For additional safety information, click here for [Full Prescribing Information](#) and discuss with your healthcare provider.

Keep Karbinal ER and all medicines out of the reach of children.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.